E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms

NCT ID: NCT02485496

Last Updated: 2022-05-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

38 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate clinical and technical success as well as safety and feasibility of the E-tegra Stent Graft System used in endovascular treatment of infrarenal aortic aneurysm.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Aortic Aneurysm AAA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endovascular abdominal repair

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EVAR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must comply with the indications for use
* Patient must have an infrarenal aortic aneurysm with diameter \>5cm or an infrarenal aortic aneurysm with 4 to 5cm that has increased in size by 0.5cm in the last 6 months
* Patient must be available for the appropriate follow-up times for the duration of the study
* Patient has signed the informed consent before intervention

Exclusion Criteria

* Patients with one of the contraindications as indicated in the instructions for use
* Patients with infectious aneurysm
* Patients with inflammatory aneurysm
* Patients with pseudoaneurysm
* Patients with ruptured or traumatic aneurysm
* Patients with suprarenal, juxtarenal, or pararenal aneurysm
* Patients with aortic dissection
* Patients with a reversed conical neck that is defined as a \>3mm distal increase over a 15mm length
* Patients who have a congenital degenerative Collagen disease or connective tissue disorder
* Patients with thrombocytopenia
* Patients with creatinine \>2.4 mg/dl immediately before the Intervention
* Patients with hyperthyreosis
* Patients with malignancy needing chemotherapy or Radiation
* Patients who are enrolled in another clinical study
* Patients with life expectancy of less than 24 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

JOTEC GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sven Seifert, Dr.

Role: PRINCIPAL_INVESTIGATOR

Klinikum Chemnitz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Nantes

Nantes, , France

Site Status

CHU Pontchaillou

Rennes, , France

Site Status

Klinikum Chemnitz

Chemnitz, , Germany

Site Status

Universitätsklinikum Leipzig

Leipzig, , Germany

Site Status

Szpital Uniwersytecki im. dr. Antoniego Jurasza

Bydgoszcz, , Poland

Site Status

Samodzielny Publiczny Szpital Kliniczny Nr 1

Lublin, , Poland

Site Status

Samodzielny Publiczny Centralny Szpital Kliniczny

Warsaw, , Poland

Site Status

Hospital Joan XXIII

Tarragona, , Spain

Site Status

Hospital Clinico Universitario Valladolid

Valladolid, , Spain

Site Status

Inselspital - Universitätsspital

Bern, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Germany Poland Spain Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SECURE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The (PIVOTAL) Study
NCT00444821 TERMINATED NA